reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
MaaT Pharma MaaT013 phase 3 beats expectations in aGvHD, MAA submissio...
MaaT announced that the phase 3 trial of MaaT013 met its primary endpoint in 3L aGvHD with a day 28 GI-ORR of 62%, exceeding our expectations and coming in in-line with our blue-sky scenario being significantly above what was observed in the phase 2 trial, and more or less in line with results from the early access program (EAP). Additionally, the company unexpectedly reported survival data showing a survival probability of 54%, higher than the 15% observed in the literature for off-label option...
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced topline results from ARES, a pivotal, single-arm, open-label, multicenter European Phase 3 study evaluating the efficacy and safety of MaaT013 in acute Graft-versus-Host Disease patients with gastrointestinal involvement (GI-aGvHD) in third-line treatment, meaning refractory to steroids and refractor...
MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Ph...
LYON, France--(BUSINESS WIRE)-- Regulatory News : (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui les résultats principaux d’ARES, une étude européenne pivotale de Phase 3 multicentrique, ouverte et à un seul bras, évaluant l'efficacité et la sécurité de MaaT013 chez des patients atteints de la maladie aiguë du greffon contre l'hôte avec atteinte gastro-...
- Florent Laroche-Joubert
- Roy Külter
ODDO : La baisse des taux d’intérêt favorise l’immobilier : nos top pi...
Le maintien d’un environnement baissier des taux d’intérêt devrait être porteur pour le secteur immobilier en 2025 et lui permettre de continuer à surperformer. Dans ce contexte, nous privilégions le commerce et le résidentiel allemand , qualifiés de «safe haven» et plus spécifiquement Covivio, CTP, Merlin Properties, URW, Vonovia et Xior Student Housing pour un potentiel moyen de +30%. Elles sont les plus à même pour nous d’exécuter leur stratégie de croissance / repositionnement. Nous abaisson...
COV COVIVIO SA
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
WHA WERELDHAVE N.V.
BLND BRITISH LAND COMPANY PLC
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
COFB COFINIMMO SA
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
LRE LAR ESPANA REAL ESTATE SOCIMI SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
SHUR SHURGARD SELF STORAGE LIMITED
- Florent Laroche-Joubert
- Roy Külter
ODDO : Interest rate winds favor real estate: Our top picks for 2025
An environment of further interest rate decline is set to underpin the real estate sector in 2025 and see it continue to outperform. On this basis, we prefer retail and the German residential market, which are seen as safe havens, more specifically Covivio, CTP, Merlin Properties, URW, Vonovia and Xior Student Housing for an average upside of +30%. They are the best positioned, as we see it, to execute their growth/repositioning strategies. We have downgraded Branicks, Cofinimmo, Icade and Patr...
COV COVIVIO SA
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
WHA WERELDHAVE N.V.
BLND BRITISH LAND COMPANY PLC
KOF KAUFMAN & BROAD SA
ALTA ALTAREA SCA
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
COFB COFINIMMO SA
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
ARG ARGAN SA
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
LRE LAR ESPANA REAL ESTATE SOCIMI SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
SHUR SHURGARD SELF STORAGE LIMITED
MaaT Pharma : Information mensuelle relative au nombre total de droits...
LYON, France--(BUSINESS WIRE)-- Regulatory News : (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 décembre 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date ...
Floridienne S.A.: 1 director
A director at Floridienne S.A. sold 2,000 shares at 510.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Jacob Mekhael
MaaT Pharma We're confident going into MaaT013's phase 3 topline in aG...
With recruitment completed for the phase 3 trial of lead program MaaT013 in aGvHD, topline data with GI-ORR is pinned for January 2025. We preview the upcoming readout and expect 15-20% upside if our base case materialises. We update our model to increase our peak sales expectations for MaaT013 in aGvHD to € 170m (from € 100m), which ups our TP to € 16 (from € 14). While this initial program represents a smaller commercial opportunity for MaaT, we see the results for MaaT013 as key to validate t...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List How to start 2025?
On this Friday the 13th we select for you 13 stocks to start 2025 with a bang : ABN Amro, Ackermans & van Haaren, Bekaert, D'Ieteren, EVS, Fagron, Fugro, Gimv, Melexis, Shurgard, Sofina, WDP and Xior However, we maintain a defensive stance in our Benelux selection at the start of 2025.. The long anticipated interest rate cuts by central banks are expected to continue their decline into 2025 (see graph above). However, the Trump election victory in the US hits European stocks even before he tak...
- Lynn Hautekeete
- Wim Lewi
Real Estate Report December 2024
BE-REITS suffer from macro-worries (logistics) and post-Trump knee-jerk reaction. We believe that especially money flows are pushing stocks down as interest rate fears resurfaced in the US. Our top-picks are Shurgard, WDP and Xior. SHUR and WDP have ample headroom on their balance sheet to continue their growth track record. WDP is also very cheap on cash earnings metrics vs. peers. Xior can grow and fix its balance sheet at the same time through contributions in kind.
LEAS LEASINVEST REAL ESTATE SCA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
IMMO COMPAGNIE IMMOBILIERE DE BELGIQUE SA
RET RETAIL ESTATES NV
MONT MONTEA SCA
AED AEDIFICA SA
QRF QRF COMM
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ASC ASCENCIO SCA
ARG ARGAN SA
VGP VGP NV
WDP WAREHOUSES DE PAUW SCA
CTPNV CTP NV
HOMI HOME INVEST BELGIUM
SHUR SHURGARD SELF STORAGE LIMITED
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Jacob Mekhael
MaaT Pharma MaaT013 EAP data shows continued benefit, phase 3 topline ...
MaaT presented updated results from the early access program (EAP) for lead candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD in Europe during the American Society of Hematology (ASH) conference. We continue to be encouraged by the strong responses observed in the subset of 58 patients resembling the population enrolled in the phase 3 (ARES) trial, which in our view provides comfort ahead of the upcoming topline readout in January 2025. We reiterate our € 14 TP and BUY rating.
CORRIGE ET REMPLACE : MaaT Pharma présente des données actualisées pos...
LYON, France--(BUSINESS WIRE)-- Regulatory News: Ce communiqué remplace celui publié le 9 décembre 2024 à 18h00 pour la raison suivante: Mise à jour du sous-titre. MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non satisfaits dans la maladie aiguë du greffon contre l’hôte (aGvH) – Inscription . Taux de réponse durable à 28 jours : le taux de réponse globale g...
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: This replaces the announcement made at 18:00 CET on 9 December 2024 due to the following corrections: Updated subheadline. MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) - Register . Sustained High Response Rates at Day 28: Gastrointestinal Overall Response Rate (GI-ORR) was 51% and Overall Response Rate (ORR) for all organs was 49%....
MaaT Pharma présente des données actualisées positives pour MaaT013 is...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET) visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, a annoncé aujourd’hui que le Professeur Florent Malard, professeur d’hématologie à l’hôpital Saint-Antoine (AP-HP) et à Sorbonne Université a détaillé les données actualisées portant sur 154 patients atteints de la maladie aiguë du greffon contre l’hôte (aGvH) traités avec MaaT01...
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Ac...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that Prof. Malard, MD, hematology professor at Saint-Antoine Hospital and Sorbonne University, today detailed updated data for 154 patients with acute Graft-versus-Host Disease (aGvHD) treated with MaaT013 in Early Access Program (EAP) in Europe during the 66th American Society of Hematology (ASH) Annual M...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Wim Lewi
- Jacob Mekhael
MaaT Pharma First US patient treated with MaaT013 under expanded acces...
MaaT announced the first treatment with MaaT013 (microbiome therapy, enema formulation) in the US of a patient with aGvHD under the FDA single patient expanded access program, which comes ahead of the planned phase 3 trial of the product in the US. In the meantime, the European study has completed recruitment with topline results (GI-ORR) expected in January 2025, and MaaT plans to commence the regulatory process in the EU soon after. We believe the chances of a good outcome are solid, supported...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.